Neurology ·
Phase I Study Reports Early Azer-cel Findings in Progressive MS
An open-label phase I study evaluated allogeneic anti-CD19 CAR T-cell therapy azer-cel in 18 adults with refractory progressive multiple sclerosis. At a median follow-up of 102 days, investigators reported no serious dose-related adverse events; most participants remained stable or improved on clinical disability measures or cerebrospinal fluid biomarkers.
- Open-label phase I study included 18 adults with refractory progressive MS.
- No serious dose-related adverse events reported over median 102-day follow-up.
- Most participants were stable or improved on reported measures.
- Small study and short follow-up limit efficacy and safety conclusions.
A phase I, open-label study evaluated azer-cel, an off-the-shelf allogeneic anti-CD19 CAR T-cell therapy designed to deplete peripheral B cells and induce immune reconstitution, in 18 adults with refractory progressive multiple sclerosis. Participants received lymphodepletion followed by one infusion, with doses ranging from 30–500 × 10⁶ CAR T cells.
At a median follow-up of 102 days, no serious dose-related adverse events were reported. Most participants remained stable or showed improvement on cerebrospinal fluid biomarker analyses and clinical disability measures. The findings were presented at MSToronto2026 and reported in a conference abstract; the small, uncontrolled phase I study and short follow-up limit conclusions about efficacy and longer-term safety. The investigators said the results support further study of azer-cel in progressive MS.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Reviews Neurology: CAR T cells show early promise in progressive multiple sclerosis ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.